Evidence map›Paper›PMID 42321169›Full record

ArticleNature communications2026

Disruption of the brain-spleen axis impairs monocyte-microglia communication and accelerates disease progression in a mouse model of amyloidosis.

Tommaso Croese, Miguel A Abellanas, Hodaya Polonsky, Michal Arad, Javier M Peralta Ramos, Yuliya Androsova, Serena Riccitelli, Sedi Medina, Francesca Palmas, Romano Strobel and 19 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Tommaso Croese *Department of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel. tommaso.croese@icloud.com.ORCID http://orcid.org/0000-0002-3805-3429
Miguel A Abellanas *Department of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.ORCID http://orcid.org/0000-0002-5680-1582
Hodaya Polonsky *Edmond & Lily Safra Center for Brain Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
Michal AradDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.
Javier M Peralta RamosDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.ORCID http://orcid.org/0000-0001-9730-9001
Yuliya AndrosovaDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.
Serena RiccitelliDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.
Sedi MedinaDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.
Francesca PalmasDepartment of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
Romano StrobelDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.ORCID http://orcid.org/0000-0002-1451-7065
Giulia CastellaniDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.
Denise KviatcovskyDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.ORCID http://orcid.org/0000-0002-9697-0380
Sarah Phoebeluc-ColaiutaDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.
Miriam AdamEdmond & Lily Safra Center for Brain Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
Sama MuradDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.
Hannah PartneyDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.
Daniel KitsbergEdmond & Lily Safra Center for Brain Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
Alexander DieterDepartment of Neurophysiology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.ORCID http://orcid.org/0000-0002-9154-4833
Tomer-Meir SalameLife Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.
Alexander BrandisLife Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.
Tevie MehlmanLife Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.
Oded SingerLife Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.ORCID http://orcid.org/0000-0002-7931-6766
Michal Rivlin-EtzionDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.ORCID http://orcid.org/0000-0002-1310-3370
Simon WiegertDepartment of Neurophysiology, MCTN, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.ORCID http://orcid.org/0000-0003-0893-9349
Yosef ShaulDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.ORCID http://orcid.org/0000-0002-0545-6512
Oren KobilerSackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.ORCID http://orcid.org/0000-0001-9914-3770
Ofer YizharDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.ORCID http://orcid.org/0000-0003-4228-1448
Naomi HabibEdmond & Lily Safra Center for Brain Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel. naomi.habib@mail.huji.ac.il.ORCID http://orcid.org/0000-0002-6049-2487
Michal SchwartzDepartment of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel. michal.schwartz@weizmann.ac.il.ORCID http://orcid.org/0000-0003-4015-7507

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is characterized by a prolonged asymptomatic phase before cognitive decline emerges, yet the mechanisms driving symptom onset remain unclear. Here, we hypothesized that the transition from asymptomatic to symptomatic disease is linked to dysfunction of brain-immune communication. Retrograde neuronal tracing in the 5xFAD mouse model of amyloidosis reveals reduced brain-spleen connectivity at advanced disease stages. To probe the functional role of the brain-spleen axis in coping with disease, we denervated the splenic nerve at an early presymptomatic stage. This intervention accelerated cognitive decline, impaired splenic hematopoiesis, diminished monocyte recruitment to the brain, disrupted monocyte-microglia signaling networks, and reduced the transition of microglia from a homeostatic to a disease-associated (DAM) state. Conversely, enhancing splenic noradrenergic input increased hematopoiesis, restored monocyte homing to the brain, and delayed cognitive impairment. The protective role of splenic monocytes was independently validated in a retinal cytotoxic injury model, in which splenic denervation impairs post-insult survival of retinal ganglion cells. Together, these findings identify an active brain-spleen circuit in regulating monocyte recruitment, and establish peripheral monocytes as important drivers of microglial state transitions and disease progression.

Indexed as

AmyloidosisBrainMicrogliaMonocytesSpleenAlzheimer DiseaseAnimalsCell CommunicationCognitive DysfunctionDisease Models, AnimalDisease ProgressionFemaleHumansMaleMiceMice, Inbred C57BL

Identifiers

PMID42321169
PMCPMC13434638

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.